12-15-2020, 09:40 AM
This is a good question, and the answer is I don't know. I think remdisivir is increasingly available (but unfortunately, demand is also up). Manufacturing for the two monoclonal antibodies is ramping up, and now that there is an EUA, I expect availability to be patchy but no longer uniquely available to the well-connected. If I were to get COVID-19, and be eligible for one of the drugs, I might ask around about availability. For example, it looks like UCSF has a treatment algorithm for when to give Bamlanivimab, which is the Lilly antibody:
https://infectioncontrol.ucsfmedicalcent...ivimab.pdf
UCSF's treatment algorithm is here:
https://infectioncontrol.ucsfmedicalcent...elines.pdf
Based on that, it looks like bamlanivimab and remdisivir may be available for patients who qualify; the Regeneron cocktail is not. Dexamethasone is widely available. UCSF's treatment documentation is here:
https://infectioncontrol.ucsfmedicalcent...ective=All
(kudos to UC for being transparent about this)
I looked up Stanford, but their online documents are less up-to-date (for example, their treatment algorithm is dated May, 2020, which in this pandemic is eons ago)
BC
https://infectioncontrol.ucsfmedicalcent...ivimab.pdf
UCSF's treatment algorithm is here:
https://infectioncontrol.ucsfmedicalcent...elines.pdf
Based on that, it looks like bamlanivimab and remdisivir may be available for patients who qualify; the Regeneron cocktail is not. Dexamethasone is widely available. UCSF's treatment documentation is here:
https://infectioncontrol.ucsfmedicalcent...ective=All
(kudos to UC for being transparent about this)
I looked up Stanford, but their online documents are less up-to-date (for example, their treatment algorithm is dated May, 2020, which in this pandemic is eons ago)
BC
